Site-directed mutagenesis of EUGO
Mutagenesis was performed by using the Quickchange mutagenesis kit from Thermo Fischer Scientific (MA, USA). Ile427 was substituted for valine, alanine and glycine and Val166 was replaced by alanine using the primers shown in Table S1 . The recipe and conditions for each of the three mutations are shown in Methods S1.
Enzyme expression, purification and storage
E.coli NEB 10-β cells were grown in 5 mL Luria-Bertani (LB) medium at 37 °C overnight to saturation.
The pre-cultures were then diluted 100 times in terrific broth (TB) medium and grown at 37 °C until the optical density measurement reached 0.6. Induction was performed by adding an amount corresponding to 0.02 % (w/v) L-arabinose to the cells and transferring the culture to 30 °C for 18 h. Expression of each of the EUGO mutants and the wild type was done in 500 mL of culture in a 2 L flask. The pBAD-EUGO-His plasmid was provided by GECCO-Biotech (Groningen, The Netherlands).
Cells were harvested by centrifugation at 6000 X g (Beckman Coulter, Avanti JE centrifuge, JLA 14 rotor) for 20 min at 4 °C. The pellets containing a mutant or the wild type enzyme were washed with Buffer A. They were then disrupted by sonication (10 min total time with cycles of 10 s on and 10 s off at 70 % amplitude) using a Sonics Vibra-Cell VCX130 probe sonicator (Newtown, CT, USA). The cellfree extract was obtained by centrifugation at 12,000 x g for 45 min at 4 °C. The extracts were filtered using Whatman FP 30/0.45 CA-S membrane syringes (GE Healthcare Lifesciences, Uppsala, Sweden)
to remove remaining cell debris.
EUGO wild type and mutant enzymes were purified by an ÄKTA purifier (GE Healthcare Lifesciences) using a 5 mL HisTrap HP column (GE Healthcare Lifesciences). The column was first equilibrated using
Buffer A followed by loading of the cell-free extract. Buffer B was then used to wash off any nonspecific proteins from the column. The enzymes were then eluted from the column by using a gradient of Buffer C starting from 0 to 500 mM imidazole within 30 min. After purification, the proteins were desalted by using the HiPrep 26/10 Desalting column (GE Healthcare Lifesciences) using Buffer D. All enzymes were frozen using liquid nitrogen and stored at -20 °C until further use. Buffer compositions are mentioned in the Supporting information, Table S2 .
Enzyme characterization
Wild type EUGO and mutant concentrations were determined based on the absorbance of the covalently bound flavin cofactor at 441 nm using the molar extinction coefficient of EUGO at 441 nm = 14. 
Biocatalytic synthesis of sinapyl alcohol
Sinapyl alcohol was synthesized in a 2 mL reaction volume in 15 mL screw-cap pyrex tubes containing 20 mM KPi pH 7, 0.5 and 5 µM EUGO I427A, 5 % (v/v) DMSO and 10 mM 2,6-dimethoxy-4-allylphenol. The experiment was conducted at 30 °C/50 rpm in an INNOVA 40 New Brunswick
Incubator Shaker (Edison, NJ, USA). The experiment was also repeated using 500 nM of EUGO mutants.
Analysis of sinapyl alcohol formation using analytical HPLC
Samples from the synthesis of sinapyl alcohol using EUGO I427A were taken at various time intervals.
The samples were centrifuged at 14,000 rpm for 10 min. The supernatant was then filtered using a Millex-FH, PTFE filter (0.45 µm pore size) (Kenilworth, NJ, USA) to remove remaining debris and then injected for analysis on a JASCO HPLC system (Easton, MD, USA). A 10 µL volume of the sample was injected into a Grace Alltima HP C18 column (3 µm, 2.1 x 100 mm, with a precolumn of the same material). As references, sinapyl alcohol and 2,6-dimethoxy-4-allylphenol (4 mM stock solutions) were also injected. The solvents used for the system were: a) water with 0.1 % v/v formic acid and b) acetonitrile with 0.08 % formic acid. The HPLC method was: 2 min 10 % B, 18 min on a gradient of 10-70 % B, 3 min 70 % B followed by a 6 s decreased gradient of 70 -10 % B and re-equilibration for 7 min. Detection was done at a wavelength of 280 nm.
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Biocatalytic synthesis of syringaresinol from 2,6-dimethoxy-4-allylphenol using EUGO I427A and HRP
Syringaresinol was synthesized from 2,6-dimethoxy-4-allylphenol using the same conditions as mentioned for the synthesis of sinapyl alcohol (see above) with the addition of an amount equivalent to 0.65 µM HRP to the reaction medium. The experiment was done using 5 µM EUGO I427A.
Analysis of syringaresinol formation using analytical HPLC and analysis of insoluble product using GPC and NMR
Syringaresinol production was analyzed using the same procedure as mentioned for the synthesis of sinapyl alcohol (see above). In addition to a soluble product, also some precipitate was formed which was isolated and analyzed after washing with water by GPC and NMR. For GPC analysis, a 10 mg/mL sample of the dried solid in THF (containing 1% toluene as internal standard) was prepared.
Subsequently, the solution was filtered (0.2 µm syringe filter) and applied on a Hewlett Packard 1100 GPC system equipped with three PL-gel 3 µm MIXED-E columns in series, a GBC LC 1240 RI detector operated at 35 °C, using THF (1 mL/min) as a mobile phase at 42 °C, calibrated on known polystyrene standards. NMR analysis was performed using a DMSO-d6 on a Bruker Ascend 600.
One gram conversion of 2,6-dimethoxy-4-allylphenol using EUGO I427A and HRP
In a 2 L flask, 250 mL reaction volume containing KPi 20 mM pH 7, EUGO I427A 3 µM, HRP 0.65 µM, DMSO 5 % (v/v) and a volume equivalent to one gram 2,6-dimethoxy-4-allylphenol was added.
The flask was placed at 30 °C/ 50 rpm and samples were routinely taken to analyze when the substrate was fully consumed. The samples were analyzed by analytical HPLC as mentioned before. The solution was filtered using a pre-weighed 47 mm glass fiber filter from PALL (Ann Arbour, MI, USA) under vacuum. The reaction mixture was extracted three times with ethyl acetate (3 x 250 mL), and then the combined organic extracts were washed with brine, dried over anhydrous MgSO4, filtered and concentrated by rotavap. The residue was purified by flash chromatography (SiO2, dichloromethane/methanol = 99:1). Table S1 . Primers used for the quickchange mutagenesis of isoleucine at 427 position in EUGO. I427V  Forward  ACGCCGCGCAATTCGTGATCGGGCTCCGC  I427V  Reverse  GCGGAGCCCGATCACGAATTGCGCGGCGT  I427A  Forward  CGCAATCGGGCTCCGCGAGATGCACCAC  I427A  Reverse  GATTGCGAATTGCGCGGCGTAGTCCTTGTTGTATTC  I427G  Forward  TCGGCATCGGGCTCCGCGAGATG  I427G  Reverse  AGCCCGATGCCGAATTGCGCGGCGTAG  V166A  Forward  GGACCGCGGCGCCGGGTACACCC  V166A Reverse GGGTGTACCCGGCGCCGCGGTCC Table S2 . M o le c u la r W e ig h t (D a ) R e la tiv e In te n s ity Figure S4 . GPC analysis of the insoluble product obtained from the biocatalytic cascade reaction of 2,6-dimethoxy-4-allylphenol (1) with EUGO I427A and HRP. C HMBC NMR analysis shown in Figure S6 ). 1 H NMR and 13 C NMR of (±)-syringaresinol purified from 1 g conversion of 2,6-dimethoxy-4-allylphenol using EUGO I427A and HRP 1 H NMR (400 MHz, CDCl3) δ 6.58 (s, 4H, H-2, 6, 2', 6'), 5.53 (s, 2H, OH), 4.73 (d, J = 3.9 Hz, 2H, H-7, 7'), 4. 2H, m, 9'), 2H, 9'), 3.89 (s, 12H, OMe), 2H, 8') .
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13 C NMR (101 MHz, CDCl3) δ 147.1 (C-3, 5, 3', 5'), 134.2 (C-4, 4'), 132.0 (C-1, 1'), 102.6 (C-2, 6, 2', 6'), 86.0 (C-7, 7'), 71.8 (C-9, 9'), 56.3 (OMe), 54.3 (C-8, 8') . 
